Showing 1431-1440 of 1717 results for "".
- Associations Between NfL Concentrations and Cognitive and Radiologic Outcomes Revealed in Study of Individuals with RMS Treated with Zeposiahttps://practicalneurology.com/news/associations-between-relapsing-ms-treatment-with-zeposia-nfl-concentrations-and-cognitive-and-radiologic-outcomes-revealed-in-1-year-interim-analysis-data/2473801/Research presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025 demonstrated that neurofilament light chain (NfL) may be a useful biomarker for both cognitive and radiologic outcomes in early relapsing multiple sclerosis (RMS). The findings resul
- Using a Salt Substitute Associated with Significant Reduction in Stroke and Death in Those with a History of Strokehttps://practicalneurology.com/news/using-a-salt-substitute-associated-with-significant-reduction-in-stroke-and-death-in-those-with-a-history-of-stroke/2473787/Replacing salt with a salt substitute in home cooking may significantly reduce risk of recurrence and all-cause mortality for people who have a history of stroke, according to data published in JAMA Neurology. Findings from a prespecified, secondary subgroup analysis of the China Salt Substitute
- 5 Year Data Show Zeposia Treatment Was Associated with Reduced Brain Volume Loss In Patients with RMShttps://practicalneurology.com/news/5-year-data-reveal-zeposia-treatment-was-associated-with-reduced-brain-volume-loss-in-patients-with-rms/2470586/Results from the phase 3 DAYBREAK open-label extension trial for Zeposia (ozanimod; Bristol Myers Squibb, New York, NY) showed sustained reductions in brain volume loss and consistent safety profiles for up to 5 years of continuous treatment in individuals with relapsing forms of multiple scleros
- Investigational Nuclear Receptor Therapy Associated with Favorable Outcomes as Potential Alzheimer Disease Treatmenthttps://practicalneurology.com/news/investigational-nuclear-receptor-therapy-associated-with-favorable-outcomes-as-potential-alzheimer-disease-treatment/2470549/Treatment with T3D-959 (T3D Therapeutics, Research Triangle Park, NC), an oral small molecule brain-penetrating PPARδ/γ dual nuclear receptor agonist, was shown to slow cognitive decline and reduce amyloid plaque burden in people with mild-to-moderate Alzheimer disease (AD). T3D-959 t
- Kesimpta Associated with Reductions in Multiple Sclerosis Disease Activity Across Race and Ethnic Groupshttps://practicalneurology.com/news/kesimpta-associated-with-reductions-in-multiple-sclerosis-disease-activity-across-race-and-ethnic-groups/2470529/Kesimpta (ofatumumab; Novartis, Cambridge, MA) was shown to be more effective than Aubagio (teriflunomide; Genzyme, Cambridge, MA) in reducing disease activity across ethnic and racial groups in people with relapsing-remitting multiple sclerosis (RRMS). Results of a post-hoc analysis of 2 previou
- PrimeC Treatment for ALS Associated With Functional Improvements and Extended Survival According to 12-Month PARADIGM Datahttps://practicalneurology.com/news/primec-treatment-for-als-associated-with-functional-improvements-and-extended-survival-according-to-12-month-paradigm-data/2470524/New 12-month results from the PARADIGM clinical trial (NCT05357950) demonstrated a significant improvement in the rate of decline of Amyotrophic Lateral Sclerosis (ALS) Functional Rating Scale-Revised (ALSFRS-R) scores and survival rates for adults with ALS treated with PrimeC (ciprofloxacin/cele
- Nasal Therapy Associated with Pain Relief for Acute Migraine Including in Those with DTT Migrainehttps://practicalneurology.com/news/nasal-therapy-associated-with-pain-relief-for-acute-migraine-including-in-those-with-dtt-migraine/2470507/New analysis of data from the phase 3 SUMMIT study (NCT04940390) demonstrated that individuals with acute migraine treated with STS101 (dihydroergotamine [DHE] nasal powder; Satsuma Pharmaceuticals, Durham, NC) reported significant improvements in headache pain relief (PR), including those with d
- Evrysdi Therapy for Type 1 Spinal Muscular Atrophy Associated with Favorable 5-Year S&E Datahttps://practicalneurology.com/news/evrysdi-therapy-for-type-1-spinal-muscular-atrophy-associated-with-favorable-5-year-se-data/2470501/Five-year data from the open-label extension of the phase 2 FIREFISH (NCT02913482) clinical trial confirms the sustained efficacy and safety profile of Evrysdi (ridisplam; Genentech, South San Francisco, CA), a treatment for children with Type 1 spinal muscular atrophy (SMA). The results demonstr
- Use of Andexanet Associated with Reduced Hematoma Volume Expansion, Increased Occurrence of Thrombotic Eventshttps://practicalneurology.com/news/use-of-andexanet-associated-with-reduced-hematoma-volume-expansion-increased-occurrence-of-thrombotic-events/2470498/According to results of a study published in The New England Journal of Medicine, people with intracerebral hemorrhage (ICH) treated with factor Xa (FXa) inhibitors who received andexanet showed reduced hematoma volume expansion compared with those who did not receive andexanet. The medi
- Wainua Treatment for hATTR-PN Associated with Improved Neuropathy Impairment and Quality of Life According to Long-Term Datahttps://practicalneurology.com/news/wainua-treatment-for-hattr-pn-associated-with-improved-neuropathy-impairment-and-quality-of-life-according-to-long-term-data/2470491/People with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN) who were treated with Wainua (eplontersen; Astra Zeneca, Cambridge, UK; Ionis Pharmaceuticals, Carlsbad, CA) for 15 months showed improvements in quality of life (QoL) and neuropathy impairment, compared to historical